PurchasingPolicy.orgPURCHASINGPOLICYBETA
← Back to Influence Map
Entity DossierOrganization

ABBVIE INC.

DC · US

Biopharmaceutical company

pharmaceuticals

Tracked direct giving

$0

Tracked donations to candidate

$0

LDA reported lobbying spend

$10,380,000

Connections

11

Lobbying Activity Detail

Disclosed lobbying expenditures from LDA filings where this entity is the client. Dollar amounts represent what was reported to the Senate Office of Public Records.

Top Lobbying Issues

HCRHealth Issues
$18.9M
MMMMedicare/Medicaid
$17.4M
TAXTaxation/Internal Revenue Code
$15.9M
CPTCopyright/Patent/Trademark
$15.1M
LBRLabor/Employment
$11.2M
TRDTrade
$6.8M
PHAPharmacy
$680K
BUDBudget/Appropriations
$600K
MEDMedical/Disease Research
$400K

Lobbying Firms Retained

ABBVIE INC.$14.9M
TARPLIN, DOWNS & YOUNG, LLC$840K
W STRATEGIES, LLC$700K
FEDERAL STREET STRATEGIES, LLC$700K
CORNERSTONE GOVERNMENT AFFAIRS, INC.$700K
MARSHALL & POPP, LLC$620K
Baker & Hostetler LLP$470K
CHECKMATE GOVERNMENT RELATIONS$180K
WILLIAMS AND JENSEN, PLLC$60K

Lobbying data from Senate LDA filings and the LobbyView dataset (MIT/NSF, CC-BY-4.0). Dollar figures represent disclosed expenditures only and may not capture all influence activity. Issue codes follow the LDA general issue classification.

Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome

Click a node to see details

Double-click to expand its connections

Relationships

TypeConnected ToDetailsSource
Lobbied forInflation Reduction Act - Energy Provisions (H.R.5376)LDA filing: lobbied on Inflation Reduction Act - Energy, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,110,000Source
Lobbied forInflation Reduction Act - Drug Pricing Provisions (H.R.5376)LDA filing: lobbied on IRA Drug Pricing Provisions, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,110,000Source
Employed byCORNERSTONE GOVERNMENT AFFAIRS, INC.Hired CORNERSTONE GOVERNMENT AFFAIRS, INC. to lobby on PharmaceuticalsSource
commented_onCenters for Medicare & Medicaid ServicesPublic comment on CMS-2023-0092: Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates under the Medicaid Drug Rebate ProgramSource
Employed byTARPLIN, DOWNS & YOUNG, LLCHired TARPLIN, DOWNS & YOUNG, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
Employed byBaker & Hostetler LLPHired BAKER & HOSTETLER LLP to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
Employed byW STRATEGIES, LLCHired W STRATEGIES, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
Employed byFEDERAL STREET STRATEGIES, LLCHired FEDERAL STREET STRATEGIES, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023)Source
Employed byMARSHALL & POPP, LLCHired MARSHALL & POPP, LLC to lobby (3rd Quarter (July 1 - Sep 30) 2023)Source
Employed byWILLIAMS AND JENSEN, PLLCHired WILLIAMS AND JENSEN, PLLC to lobby (1st Quarter (Jan 1 - Mar 31) 2026)Source
Employed byCHECKMATE GOVERNMENT RELATIONSHired CHECKMATE GOVERNMENT RELATIONS to lobby (1st Quarter (Jan 1 - Mar 31) 2026)Source